The Defense Health Agency awarded Cedars-Sinai Medical Center a $501,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant, titled "LARGE ONCOSOMES AS DRIVERS OF PROSTATE CANCER BONE METASTASIS", will fund advanced biomedical research aimed at transforming healthcare for military service members and the broader public. The research will investigate the role of large oncosomes in prostate cancer bone metastasis, with the goal of...
The Department of Defense's Defense Health Agency awarded a $1,164,294 Project Grant to Cedars-Sinai Medical Center on September 15, 2024 under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund a 4-year project to correlate prostate-specific membrane antigen (PSMA) expression with molecular profiles in prostate cancer. Cedars-Sinai, a non-profit hospital and academic medical center, will conduct this biomedical research to advance understanding of...
The Defense Health Agency awarded a $974,043 Project Grant to Cedars-Sinai Medical Center under the Military Medical Research and Development (CFDA 12.420) program. The grant supports early cardiac biomarker research focused on inflammation and remodeling in Duchenne muscular dystrophy. This 4-year award, running from September 1, 2025 to August 31, 2029, will fund innovative biomedical investigations at Cedars-Sinai aimed at transforming healthcare for military service members and the broader...
The Defense Health Agency awarded Cedars-Sinai Medical Center a $2,674,057 Project Grant under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective June 1, 2025 through May 31, 2029, will support advanced biomedical research to identify pathways of progression from acute pancreatitis to recurring acute pancreatitis and chronic pancreatitis. As a leading academic medical research center, Cedars-Sinai will leverage its expertise in translational research,...
The Defense Health Agency awarded a $997,343 Project Grant to Cedars-Sinai Medical Center under the Military Medical Research and Development (CFDA 12.420) program. The grant supports a multidimensional imaging data-driven approach for phenotyping multiple sclerosis. The research aims to transform healthcare for military service members and the broader public through innovative and impactful biomedical investigations spanning basic, applied, and translational research. The award period runs from...
Cedars-Sinai Medical Center will receive $501,000 through a two-year Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support the medical center's research project "CD44 Enhances Efficacy of the Chimeric Antigen Receptor T-Cell Therapy Against Prostate Cancer." Through this funding, Cedars-Sinai researchers will investigate using CD44 to improve the effectiveness of CAR T-cell therapy in treating...
The Department of the Army Medical Command awarded Cedars-Sinai Medical Center a $1,252,233 Project Grant on September 30, 2022 to support research titled "NOVEL LINEAGE PLASTICITY INHIBITORS IN PROSTATE CANCER." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine and other health issues. Under this award, Cedars-Sinai...
The federal Project Grant award of $598,130.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support research conducted by Cedars-Sinai Medical Center to investigate the determinants of lung cancer-associated cachexia. The research aims to transform healthcare for military service members and the broader public by advancing innovative and impactful biomedical research. The award, effective from February 15, 2025 to February 14, 2027, will...
The U.S. Department of Defense awarded a $1,000,000.00 Project Grant to Cedars-Sinai Medical Center under the Military Medical Research and Development program (CFDA 12.420) to evaluate short- and long-term systemic anti-tumor immunity following combined radiation and immunotherapy in triple-negative breast cancer. This 4-year research project, which commenced on Sep 15, 2023 and is scheduled for completion by Sep 14, 2027, aims to investigate medical solutions for transforming healthcare for...
This $1,251,673.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Cedars-Sinai Medical Center on August 1, 2023. The grant will fund research aimed at re-engineering the intratumoral myeloid-macrophage compartment to enhance the response to radiation and immunotherapy in triple-negative breast cancer. The three-year project will be performed at Cedars-Sinai's facilities in West Hollywood, CA. As a leading...